Literature DB >> 64046

Pharmacokinetic study with synthetic salmon calcitonin (Sandoz).

T Beveridge, W Niederer, E Nüesch, A Petrin.   

Abstract

18 patients randomly divided into 3 groups of six each received 35 mug (140 M.R.C. Units) of synthetic salmon calcitonin intravenously, intramuscularly or subcutaneously. Plasma and urin concentrations were determined using the radioimmunoassay method. There was a rapid distribution phase of ca. 12 minutes after intravenous injection then an elimination half-life of 1.1 hours. The volume of distribution was 11 litres. The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively. The bioavailability of the intramuscular and subcutaneous forms was found to be 66 and 71% respectively when areas under their plasma concentration/time curves were compared with the intravenous area.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 64046

Source DB:  PubMed          Journal:  Z Gastroenterol Verh        ISSN: 0172-8504


  8 in total

1.  Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).

Authors:  P J Sinko; Y H Lee; V Makhey; G D Leesman; J P Sutyak; H Yu; B Perry; C L Smith; P Hu; E J Wagner; L M Falzone; L T McWhorter; J P Gilligan; W Stern
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

3.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

4.  Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin.

Authors:  R Franceschini; A Cataldi; T Barreca; M Salvemini; E Rolandi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

6.  [Calcitonin.].

Authors:  C Maier
Journal:  Schmerz       Date:  1990-03       Impact factor: 1.107

7.  Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus.

Authors:  A Starke; E Keck; M Berger; H Zimmermann
Journal:  Diabetologia       Date:  1981-05       Impact factor: 10.122

8.  Prolonged hypocalcemic effect by pulmonary delivery of calcitonin loaded poly(methyl vinyl ether maleic acid) bioadhesive nanoparticles.

Authors:  J Varshosaz; M Minaiyan; M Forghanian
Journal:  Biomed Res Int       Date:  2014-02-20       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.